Newsroom

Summary of the quarter January – March 2026 (January – March 2025) · Net sales for the first quarter amounted to 29.3 (9.0) MSEK, an increase of 20.3 MSEK. Sales growth has been strong during the quarter, particularly driven by large deliveries in Europe. · Operating profit for the quarter amounted to 4.1 (-7.8) MSEK. · Profit for the quarter was 4.7 (-8.0) MSEK. · Cash flow for the period amounted to +6.3 (-4.4) MSEK · Order intake for the first quarter totaled 15.5 (31.6) MSEK, a decrease of 16.1 MSEK (order value converted at the exchange rate at the time of order).

Bio-Works Technologies AB has received an order for 230 liters of WorkBeads 40S, valued at approximately 4,2 million SEK, from a returning European customer active in contract manufacturing of peptides. “The order confirms the continued confidence in Bio-Works as a supplier of high-quality chromatography products and highlights the strong position of WorkBeads 40S in the growing peptide purification market,” says Lone Carlbom, CEO of Bio-Works Technologies AB. Delivery is planned for Q3 2026, and the order contributes positively to Bio-Works’ sales targets for the year. Contacts:

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. On 16 April 2026, the sixth exercise period for Bio-Works Technologies AB's (“

Bio-Works Technologies AB has  been awarded  over 1.5M SEK by Vinnova, the Swedish grant authority, to develop [...]

Bio-Works opens a US sales office, marking a key step in expanding its presence in the world's largest biopharmaceutical market.

Bio-Works' WorkBeads resins are used in full-scale commercial production of an FDA-approved biopharmaceutical, validating the product's quality and reliability.